AbbVie Sees Cash Tax Savings from $3.4 Trillion Law’s R&D, CapEx Deductions
AbbVie reported lower federal cash taxes driven by accelerated deductions for research, equipment and capital expenditures under the $3.4 trillion tax overhaul. This aligns with a $65 billion decline in US corporate tax revenues as effective tax rates reach historic lows.
1. US Corporate Tax Overhaul Reduces Revenues
The $3.4 trillion corporate tax overhaul implemented in 2025 has driven US Treasury corporate tax receipts down by $65 billion, from $489 billion in 2024 to $424 billion in 2025. Estimates indicate average corporate tax burdens fell roughly 15%, with accelerated deductions front-loading benefits for capital-intensive and research-driven firms.
2. AbbVie Cites Accelerated Deductions Benefits
AbbVie reported lower federal cash taxes, attributing significant savings to accelerated deductions for research, equipment and other capital expenditures under the new law. These benefits mirror similar gains at other companies and are expected to support AbbVie’s cash flow generation through the early phase of the legislation’s implementation.